サンプル依頼リスト カート
  • English
  • Korean
表紙：難治性多発性骨髄腫の世界市場-2023年～2030年
市場調査レポート
商品コード
1297803

難治性多発性骨髄腫の世界市場-2023年～2030年

Global Refractory Multiple Myeloma Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
難治性多発性骨髄腫の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

難治性多発性骨髄腫の世界市場は、2022年に24億米ドルに達し、2030年には34億米ドルに達するなど、有利な成長が予測されています。世界の難治性多発性骨髄腫市場は、2023～2030年の予測期間中に4.7%のCAGRを示すと予測されます。技術の進歩や新薬の臨床試験の増加が、難治性多発性骨髄腫の市場動向を牽引しています。

多発性骨髄腫は依然として不治の病ですが、カルフィルゾミブ、ボルテゾミブ、イキサゾミブなどのプロテアソーム阻害剤（PI）や、レナリドミド、サリドマイド、ポマリドミドなどの免疫調節薬の開発により、過去15年間で医療は改善しました。

難治性多発性骨髄腫の市場範囲は、プロテアソーム阻害剤、免疫調節剤、抗 CD38モノクローナル抗体、キメラ抗原受容体（CAR-T）療法、その他などの薬剤タイプで構成され、難治性多発性骨髄腫の市場シェアを拡大しています。

難治性多発性骨髄腫の世界市場は、研究開発の増加や各国における今後の新規製品承認などの要因により拡大しており、難治性多発性骨髄腫市場の成長にも明るい見通しが生まれています。

市場力学

新製品上市の増加が難治性多発性骨髄腫市場の成長を促進します

過去数年間、多発性骨髄腫研究のための新規製品上市の数はかなり増加しています。難治性多発性骨髄腫治療を改善するために、世界的に数多くの研究が行われています。最近の調査によると、多発性骨髄腫（MM）患者は、生存期間を延長するために長期的かつ継続的な治療を必要としています。

例えば、2022年12月8日、Folotynのジェネリック代替品として、プララトレキサート注射液が、再発または耐性化した末梢性T細胞リンパ腫の治療薬として、ヘルスケア企業であるFresenius Kabi社から発売されました。米国ヘルスケアにおける注射可能な腫瘍治療薬の最大のラインナップに新たに加わったのが、フレゼニウス・カビ社のプララトレキサート注です。

再発性または難治性の末梢性T細胞リンパ腫の成人患者には、フレゼニウス・カビ・プララトレキサート注射液というジェネリック医薬品の治療選択肢があります。Fresenius Kabi Pralatrexate Injectionには、40mg/2mLと20mg/1mLの2種類の単回用量バイアルがあります。

規制当局の承認とパイプラインの増加は、メーカーに有利な機会を創出します

多くの研究者やフェローによる臨床研究や基礎科学研究への貢献は、新規治療法の開発を加速させ、疾患の起源や経過に関する理解を著しく向上させています。いくつかの臨床試験が実施され、肯定的な結果をもたらしています。

例えば、2023年5月16日、ロシュ・グループの子会社であるジェネンテック社から、再発型多発性硬化症（RMS）の患者を対象に実験的な経口フェネブルチニブを試験するFENopta試験の第2相から得られた良好な結果が発表されました。

この調査では、経口フェネブルチニブがプラセボと比較して、脳のMS疾患活動性を示す磁気共鳴画像（MRI）マーカーを有意に減少させ、1次調査と2次調査を達成したことが示されました。さらに、前臨床試験では、現在MSを対象とした第III相試験で試験されている唯一の可逆的阻害剤であるフェネブルチニブの効力と優れた選択性が示されました。

薬剤に関連する副作用が市場の成長を妨げます

しかし、治療負担は依然としてMM治療の期間を短くしています。そのため、治療による患者のQOLへの悪影響を軽減する方法を開発することが極めて重要です。血小板減少や好中球減少のような血液学的副作用、悪心、嘔吐、下痢のような消化器系副作用、深部静脈血栓症や肺塞栓症のような静脈血栓性副作用、発疹や末梢神経障害のような副作用は、これらの治療に関連する最も頻繁に報告される問題です。

自宅で経口薬を服用している患者は、できるだけ早く、できれば治療が困難になる前に症状を報告すべきです。MM療法が効果的で、長続きし、実用的であるかどうかは、このような治療関連の副作用を適切に管理し、食事療法と薬物療法の組み合わせをモニターし、患者の自己負担費用を援助するかどうかにかかっています。

COVID-19の影響分析

COVID-19の流行と世界の封鎖は、あらゆる業界の企業の財務状況に影響を及ぼしています。その結果、米国食品医薬品局（FDA）は、COVID-19健康緊急事態に対するガイドラインを発表しました。このガイドラインには、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）に従い、試験の完全性に対するリスクを低減するための一般的な考慮事項が含まれています。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、世界の難治性多発性骨髄腫市場に与える影響は低いと推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の難治性多発性骨髄腫市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響因子
    • 促進要因
      • 新製品上市の増加
      • 多発性骨髄腫の発生率の増加
    • 抑制要因
      • 治療に伴う副作用
    • 機会
      • 規制当局の承認とパイプラインの増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤タイプ別

  • プロテオソーム阻害剤
  • 免疫調節薬
  • 抗CD38モノクローナル抗体
  • その他

第8章 投与経路別

  • 経口
  • 非経口

第9章 製品タイプ別

  • 錠剤
  • カプセル剤
  • 溶液
  • 懸濁液

第10章 エンドユーザー別

  • 病院
  • 手術センター/クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東およびアフリカ
    • 主な地域別力学

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Bristol Myers Squibb
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Janssen Global Services, LLC
  • Gilead Sciences, Inc.
  • Fresenius Kabi
  • GSK plc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Genentech, Inc.

第14章 付録

目次
Product Code: PH6465

Market Overview

The Global Refractory Multiple Myeloma Market reached US$ 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 3.4 billion by 2030. The Global Refractory Multiple Myeloma Market is expected to exhibit a CAGR of 4.7% during the forecast period 2023-2030. The increasing technological advancements and the growing clinical trials for novel drugs drive demand for refractory multiple myeloma market trends.

Even though MM is still incurable, medical care has improved over the past 15 years thanks to the development of proteasome inhibitors (PIs) such as carfilzomib, bortezomib, and ixazomib as well as immunomodulatory medications like lenalidomide, thalidomide, and pomalidomide.

The refractory multiple myeloma market scope comprises drug type as proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibodies, chimeric antigen receptor (CAR-T) therapy and others, which has increased the refractory multiple myeloma market share.

The global market for refractory multiple myeloma is expanding due to factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the refractory multiple myeloma market growth.

Market Dynamics

The Rising Novel Product Launches Drive the Growth of the Refractory Multiple Myeloma Market.

Over the past few years, there has been a considerable increase in the number of novel product launches for multiple myeloma research. Numerous studies are being carried out globally to improve refractory multiple myeloma treatment to study the illness. According to recent research, multiple myeloma (MM) patients need long-term, ongoing treatment to increase survival.

For instance, on December 8, 2022, as a generic alternative to Folotyn, Pralatrexate Injection has been made available by the healthcare company Fresenius Kabi for the treatment of peripheral T-cell lymphoma that has returned or become resistant. The newest addition to the greatest array of injectable oncology medications in American healthcare is Fresenius Kabi Pralatrexate Injection, which is currently available in the country.

Adult patients with recurrent or refractory peripheral T-cell lymphoma have a generic therapeutic option with Fresenius Kabi Pralatrexate Injection. There are two single-dose vial presentations of Fresenius Kabi Pralatrexate Injection: 40 mg/2 mL and 20 mg/1 mL.

Rising Regulatory Approval and Pipeline Creates Lucrative Opportunities for Manufacturers.

Contributions to clinical research and fundamental science research from a number of researchers or fellows have accelerated the development of novel treatments and significantly improved the understanding of the origins and course of disorders. Several clinical trials are being conducted, resulting in positive outcomes.

For instance, on May 16, 2023, Positive findings from the second phase of the FENopta study testing experimental oral fenebrutinib in people having relapsing types of multiple sclerosis (RMS) were released by Genentech, a subsidiary of the Roche Group.

The research demonstrated that oral fenebrutinib significantly decreased magnetic resonance imaging (MRI) markers for MS disease activity in the brain when compared to placebo, demonstrating that it accomplished its primary and secondary goals. In addition, pre-clinical studies showed the potency and good selectivity of fenebrutinib, the one and only reversible inhibitor now being tested in Phase III studies for MS.

Side Effects Linked with Drugs will Hamper the Growth of the Market.

However, the treatment burden still shortens the duration of MM therapy; as a result, it is crucial to develop ways to reduce the negative effects of treatment on the patient's quality of life. Hematologic side effects like thrombocytopenia and neutropenia, gastrointestinal side effects like nausea, vomiting, and diarrhea, venous thrombotic side effects like deep-vein thrombosis or pulmonary embolism, and side effects like rash and peripheral neuropathy are the most frequently reported problems associated with these treatments.

Patients taking oral medicines at home should report symptoms as soon as possible, preferably before they become challenging to treat. Effective, long-lasting, and practical MM therapy depends on properly managing such treatment-related adverse effects, monitoring both dietary and drug combinations, and assisting with out-of-pocket expenses for patients.

COVID-19 Impact Analysis

The COVID-19 epidemic and the worldwide lockdown have affected the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP), and reduce risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global refractory multiple myeloma market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global refractory multiple myeloma market growth over the forecast period.

Segment Analysis

The Global Refractory Multiple Myeloma Market is segmented based on drug type, route of administration, product type, end user and region.

Oral from Drug Type Segment Accounts for 76.3% of the Market Share. Owing to Rising Availability

In the era of new therapeutics, oral MM regimens often consist of an immunomodulatory medication plus a corticosteroid (most commonly dexamethasone) or an immunomodulatory medication plus a corticosteroid or an alkylating agent (like cyclophosphamide and dexamethasone [Cd] or melphalan and prednisone [MP]).

Although compared to the standard of treatment lenalidomide-dexamethasone (Rd), lenalidomide cyclophosphamide-prednisone and the triplet regimens lenalidomide with MP (MPR) be not particularly beneficial. As seen with bortezomib, carfilzomib, and ixazomib when combined with Rd, studies have indicated that an immunomodulatory drug- or PI-containing triplet therapy is particularly effective at eliciting rapid, profound responses and enhancing progression-free survival.

An alloral immunomodulatory medication and PI-containing triplet regimen is accessible with the recent US Food and Medication Administration (FDA) clearance of ixazomib when combined with Rd for individuals with MM who have undergone at least one prior therapy. Pomalidomide with dexamethasone or Cd is another active all-oral regimen for individuals with relapsed illness.

Geographical Analysis

North America Accounted for Approximately 42.7% of the Market Share, Owing to the Strong Presence of Major Players and Rising Technological Advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for refractory multiple myeloma for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of refractory multiple myeloma, increasing demand.

There are many manufacturers and suppliers in North America. As a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the treatment of multiple myeloma.

The market will grow as new items or technology for treatment emerge. Rising technological developments, governmental approvals, and introducing of new products contribute to growth. People are becoming more aware of novel technologies and myelomas, expanding the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the refractory multiple myeloma market include: Bristol Myers Squibb, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Janssen Global Services, LLC, Fresenius Kabi, Gilead Sciences, Inc., GSK plc., Takeda Pharmaceutical Company Limited, Novartis AG and Genentech, Inc. among others.

Why Purchase the Report?

  • To visualize the Global Refractory Multiple Myeloma Market segmentation based on drug type, route of administration, product type, end user and region, and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous refractory multiple myeloma market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Refractory Multiple Myeloma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Product Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Novel Product Launches
      • 4.1.1.2. Increasing Incidence of Multiple Myeloma
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with the Treatment
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Regulatory Approval and Pipeline
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Proteosome Inhibitor *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Immunomodulators
  • 7.4. Anti-CD38 Monoclonal Antibody
  • 7.5. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By Product Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.1.2. Market Attractiveness Index, By Product Type
  • 9.2. Tablet *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Capsule
  • 9.4. Solution
  • 9.5. Suspension

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Surgical Centres/ Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan

Australia

      • 11.5.7.4. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Bristol Myers Squibb *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Teva Pharmaceutical Industries Ltd.
  • 13.3. Pfizer Inc.
  • 13.4. Janssen Global Services, LLC
  • 13.5. Gilead Sciences, Inc.
  • 13.6. Fresenius Kabi
  • 13.7. GSK plc.
  • 13.8. Novartis AG
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Genentech, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us